EUVIMEDEUVIMED entdecken
Crossref

Synbiotic to Attenuate Resorption of the Skeleton (STARS): Design and participant recruitment of a randomized, double-blind, placebo-controlled trial to test the efficacy of SBD111 medical food in older women

Josie G Ford, Evelyn O'Neill, Catherine Tolland, Thomas G Travison, Karl Singer, Mark R Charbonneau, D Davidson Easson, Paul F Jacques, Gerardo V Toledo, Clifford J Rosen, Eric M Schott, Douglas P Kiel und 1 weitere

Contemporary Clinical Trials · 2026-12 · 171 · 108501

DOI: 10.1016/j.cct.2026.108501 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Contemporary Clinical Trials, 2026-12. Verfasst von Josie G Ford und 12 weiteren Autor:innen. Beteiligte Einrichtung: Hinda and Arthur Marcus Institute for Aging Research, Hebrew SeniorLife, Roslindale, MA, United States of America; University of Connecticut School o…. Die Arbeit nennt 45 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Osteoporosis and related fractures pose a costly public health challenge. Primary prevention of bone loss is largely limited to non-pharmacologic options without consistent guidelines. Prior studies have demonstrated that modification of the gut microbiome can influence bone homeostasis. The Synbiotic To Attenuate Resorption of the Skeleton (STARS) trial aimed to evaluate the efficacy, safety, and mechanistic effects of daily intake of SBD111, a fruit and vegetable-derived synbiotic medical food on the skeleton, gut microbiome, and inflammation biomarkers in women aged ≥60 years. This 18-month, investigator-initiated, single-site, randomized, double-blind, placebo-controlled trial had an enrollment goal of 220 women, a primary endpoint of proportionate change in lumbar spine bone mineral density (BMD) relative to baseline, and secondary outcomes including Quantitative Computed Tomography derived volumetric BMD and vertebral compressive strength, gut microbiome function, and bone and inflammatory biomarkers. Recruitment approaches included simultaneous digital and traditional methods beginning August 2024. As of July 2025, there were 42 enrolled participants (32 via digital, 10 via traditional); baseline demographics, eligibility, and enrollment rates were similar across recruitment strategies. Digital recruitment achieved over three times faster enrollment (2.9 vs. 0.9 enrollments/month) and was nearly 10 times more staff-efficient (0.05 vs. 0.48 cumulative weekly full-time equivalent) despite greater cost per enrollment ($548 vs. $173). These findings demonstrate the feasibility and efficiency of digital recruitment of older adults, offering valuable insights for future nutrition and microbiome clinical trials. The STARS trial is positioned to provide high-quality evidence for skeletal health maintenance in older women using SBD111.

Schlagwörter

Stichwörter der Autor:innen

Bone mineral densityBone turnoverMicrobiomeOlder womenPostmenopausalRandomized clinical trialSynbiotic

Autor:innen und Institutionen

  • Hinda and Arthur Marcus Institute for Aging Research, Hebrew SeniorLife, Roslindale, MA, United States of America; University of Connecticut School of Medicine, Farmington, CT, United States of America.
  • Hinda and Arthur Marcus Institute for Aging Research, Hebrew SeniorLife, Roslindale, MA, United States of America.
  • Hinda and Arthur Marcus Institute for Aging Research, Hebrew SeniorLife, Roslindale, MA, United States of America; Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United…
  • Sōlaria Biō Inc., Waltham, MA, United States of America.
  • USDA Human Nutrition Research Center on Aging, Friedman School of Nutrition, Tufts University, Boston, MA, United States of America.
  • Maine Medical Center, Portland, ME, United States of America.

Zitieren

APA

Ford, J. G., O'Neill, E., Tolland, C., Travison, T. G., Singer, K., Charbonneau, M. R., Easson, D. D., Jacques, P. F., Toledo, G. V., Rosen, C. J., Schott, E. M., Kiel, D. P., & Sahni, S. (2026). Synbiotic to Attenuate Resorption of the Skeleton (STARS): Design and participant recruitment of a randomized, double-blind, placebo-controlled trial to test the efficacy of SBD111 medical food in older women. Contemporary Clinical Trials, 171, 108501. https://doi.org/10.1016/j.cct.2026.108501

Vancouver

Ford JG, O'Neill E, Tolland C, Travison TG, Singer K, Charbonneau MR, et al. Synbiotic to Attenuate Resorption of the Skeleton (STARS): Design and participant recruitment of a randomized, double-blind, placebo-controlled trial to test the efficacy of SBD111 medical food in older women. Contemporary Clinical Trials. 2026;171:108501. doi:10.1016/j.cct.2026.108501

BibTeX
@article{Ford2026,
  author = {Ford, Josie G and O'Neill, Evelyn and Tolland, Catherine and Travison, Thomas G and Singer, Karl and Charbonneau, Mark R and Easson, D Davidson and Jacques, Paul F and Toledo, Gerardo V and Rosen, Clifford J and Schott, Eric M and Kiel, Douglas P and Sahni, Shivani},
  title = {Synbiotic to Attenuate Resorption of the Skeleton (STARS): Design and participant recruitment of a randomized, double-blind, placebo-controlled trial to test the efficacy of SBD111 medical food in older women},
  journal = {Contemporary Clinical Trials},
  year = {2026},
  volume = {171},
  pages = {108501},
  doi = {10.1016/j.cct.2026.108501}
}
Kostenlos starten →